drugset / Trial / NCT03623581
Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, phase 2 trial of Geptanolimab in patients with initially unresectable, recurrent or metastatic ASPS. The study aims to study the activity of Geptanolimab assessed per RECIST 1.1 and iRECIST criteria, and safety profile.
Timeline
- Start
- 2018-09-06
- Primary completion
- 2021-08
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APL-501 | Monoclonal antibody | 3 mg/kg | Intravenous |